Plunkett Research Online: Millendo Therapeutics Inc

MILLENDO THERAPEUTICS INC (MLND:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Millendo Therapeutics Inc is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases. Its lead asset, livoletide, is an unacylated ghrelin analogue being developed for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease characteriz.....



Millendo Therapeutics Inc
Ticker: MLND
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 734 845-9000
Fax:
Address: 301 North Main Street
Suite 100
Ann Arbor, MI 48104 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
Contacts Description

Julia Owens CEO/Director/President
Louis Arcudi CFO/Chief Accounting Officer
See More
Millendo Therapeutics Inc is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases. Its lead asset, livoletide, is an unacylated ghrelin analogue being developed for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease characteriz.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2020 2019 2018 2017 2016 2015
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Name Title Salary (US$) Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: